FDA Approves Guardant360 Liquid CDx for Advanced Cancer Treatment
The FDA has approved the Guardant360® Liquid CDx, which is a comprehensive blood-based genomic testing panel designed to provide genomic and epigenomic insights for better treatment decisions in advanced cancer patients. This panel is the largest of its kind to receive FDA approval.
PALO ALTO, Calif.–(BUSINESS WIRE)–Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360® Liquid CDx, advancing blood-based comprehensive genomic testing by integrating genomic and epigenomic insights and helping clinicians make better-informed treatment selection decisions for patients with advanced cancer. Guardant360 Liquid CDx is the largest FDA-approved liquid biopsy panel, assess